AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business Officer

NEW YORK--(BUSINESS WIRE)--#NSCLC--AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company developing novel precision oncology therapeutics, today announced the appointment of Edward Lang Jr. as Chief Business Officer.

With more than 20 years of experience in the biotechnology industry, Lang will join the executive leadership team and oversee business development, communications, and investor relations. He will also be responsible for building AnHeart’s initial commercial capabilities.

“We’re delighted to welcome Ed to AnHeart Therapeutics. He has a deep knowledge of corporate strategy, a proven track record of raising capital, and extensive experience in launching cancer medicines,” said Junyuan (Jerry) Wang, Ph.D., CEO & Co-Founder, AnHeart Therapeutics. “Ed will be an invaluable asset to AnHeart and our leadership team as we further advance our clinical pipeline of cancer medicines and move closer towards commercialization.”

“Ed brings to AnHeart more than two decades of experience leading high-performing teams and supporting multiple oncology product launches. He has a proven track record of success on both the operating and business development sides of our industry, and we look forward to working together as AnHeart enters its next stage of growth,” said Lihua Zheng, J.D., Ph.D., Co-Founder and Chief Strategy Officer.

Prior to joining AnHeart, Lang served as Chief Business Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. Lang previously served as Vice President, Corporate Affairs at Juno Therapeutics, acquired by Celgene. Prior to that he spent 13 years at Genentech supporting the approval and launch of 15 new medicines.

“I am excited to join AnHeart at such an important time in the company’s growth and look forward to working with Jerry and the team,” said Edward Lang Jr., Chief Business Officer. “With a strong pipeline of medicines, I believe AnHeart has the opportunity to make a meaningful impact on the lives of people with cancer – especially in areas where current medicines fail to meet patients’ needs.”

About AnHeart Therapeutics

AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China. For more information, visit www.anhearttherapeutics.com.

Investor Contact:
Weiqing Wang, PhD
212-466-6378
ir@anhearttherapeutics.com

Media Contact:
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com